Kontafarma China Holdings Ltd
1312.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$184.1M
Close$
Share Statistics
| Market cap | $184.10 Million |
|---|---|
| Enterprise Value | $420.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | -0.02 |
| Outstanding Shares | 5,578,713,777 |
Return
| Return on Equity | -112.81% |
|---|---|
| Return on Assets | -57.71% |
| Return on Invested Capital | -73.82% |
Valuation & Multiples
| P/E Ratio | -0.86 |
|---|---|
| PEG | 1.13 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.24 |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | 0.6 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kontafarma China Holdings Ltd
625 employees
CEO: Feifei Wang Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated ...